🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sutton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sutton

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC25 AstraZeneca25 Merck Sharp & Dohme LLC12 Seagen, a wholly owned subsidiary of Pfizer10 Novartis Pharmaceuticals10
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
220 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
London, Sutton
2025-07-31
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
NCT07079631Metastatic Colorectal Cancer
BioNTech SE
Phase 1/2
482
London, Manchester, Sutton
2025-07-18
Recruiting
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
140
Manchester, Sutton
2025-07-07
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
NCT06855277Prostate Cancer
Novartis Pharmaceuticals
Phase 3
940
Sutton, London
2025-07-01
Recruiting
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT06850623Locally Advanced Pancreatic Adenocarcinoma
EXACT Therapeutics AS
Phase 2
25
Cambridge, Hammersmith, Sutton
2025-06-19
Recruiting
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
NCT06941272Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 1/2
50
Birmingham, Newcastle upon Tyne, Cardiff, Sutton
2025-05-26
Recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
NCT06522737Lymphoma
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
Boehringer Ingelheim
Phase 1
91
London, Sutton
2025-05-14
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,440
Cambridge, London, Exeter, Birmingham, Northwood, Sutton, Devon
2025-05-13
Active, closed
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
NCT06932952Solid Tumor
Byondis B.V.
Phase 1
7
Manchester, Sutton
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
London, Liverpool, Sutton, Manchester
2025-05-06
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
AbbVie
Phase 2
390
London, Oxford, Sutton, Manchester
2025-04-24
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
BioNTech SE
Phase 1/2
380
Cambridge, Cardiff, Leeds, London, Manchester, Sutton
2025-04-23
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
NCT06843447Ovarian Cancer Recurrent
Merck Sharp & Dohme LLC
Phase 1/2
605
Brighton, Fulham, Sutton, London, Manchester
2025-04-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Merck Sharp & Dohme LLC
Phase 3
770
Cambridge, Edinburgh, Preston, London, Sutton, Birmingham, Leicester, Liverpool
2025-04-09
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
London, Sutton
2025-04-07
Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
NCT06914128MTAP-deleted Solid Tumors
Bayer
Phase 1/2
450
Manchester, Sutton
2025-03-21
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 3
840
Cambridge, Coventry, Dundee, London, Manchester, Sutton
2025-03-01
Recruiting
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
NCT06764316Hepatocellular Carcinoma
Bayer
Phase 1
148
London, Glasgow, Sutton
2025-02-28
Recruiting
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
NCT06567782Neoplasms, Colon
GlaxoSmithKline
Phase 2
120
Glasgow, Leeds West Yorkshire, London, Sutton
2025-02-18
Recruiting
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
NCT06800313Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2
190
Sutton
2025-02-06
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355Extensive-stage Small-cell Lung Cancer
BioNTech SE
Phase 3
621
Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee
2025-02-03
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
Pfizer
Phase 3
1,035
Harlow, Truro, Maidstone, Taunton, Sutton, Coventry, Guildford, London
2025-01-06
Rows per page Showing 26–50 of 220
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/sutton

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.